Quantitative assessment of adaptive radiotherapy for prostate cancer using deep learning: Bladder dose as a decision criterion

• Published in: Medical physics (Lancaster) 2023-10, Vol.50 (10), p.6479-6489
• Main Authors: Wan, Luping, Jiang, Yin, Zhu, Xianggao, Wu, Hao, Zhao, Wei
• Format: Article
• Language: English
• ISSN: 0094-2405; 2473-4209
• DOI: 10.1002/mp.16710

BACKGROUNDAdaptive radiotherapy (ART) can incorporate anatomical variations in a reoptimized treatment plan for fractionated radiotherapy. An automatic solution to objectively determine whether ART should be performed immediately after the daily image acquisition is highly desirable. PURPOSEWe investigate a quantitative criterion for whether ART should be performed in prostate cancer radiotherapy by synthesizing pseudo-CT (sCT) images and evaluating dosimetric impact on treatment planning using deep learning approaches. METHOD AND MATERIALSPlanning CT (pCT) and daily cone-beam CT (CBCT) data sets of 74 patients are used to train (60 patients) and evaluate (14 patients) a cycle adversarial generative network (CycleGAN) that performs the task of synthesizing high-quality sCT from daily CBCT. Automatic delineation (AD) of the bladder is performed on the sCT using the U-net. The combination of sCT and AD allows us to perform dose calculations based on the up-to-date bladder anatomy to determine whether the original treatment plan (ori-plan) is still applicable. For positive cases that the patients' anatomical changes and the associated dose calculations warrant re-planning, we made rapid plan revisions (re-plan) based on the ori-plan. RESULTSThe mean absolute error within the region-of-interests (i.e., body, bladder, fat, muscle) between the sCT and pCT are 41.2, 25.1, 26.5, and 29.0HU, respectively. Taking the calculated results of pCT doses as the standard, for PTV, the gamma passing rates of sCT doses at 1 mm/1%, 2 mm/2% are 87.92%, 98.78%, respectively. The Dice coefficients of the AD-contours are 0.93 on pCT and 0.91 on sCT. According to the result of dose calculation, we found when the bladder volume underwent a substantial change (79.7%), the bladder dose is still within the safe limit, suggesting it is insufficient to solely use the bladder volume change as a criterion to determine whether adaptive treatment needs to be done. After AD-contours of the bladder using sCT, there are two cases whose bladder dose D mean > 4000 cGy ${{\mathrm{D}}}_{{\mathrm{mean}}} > 4000{\mathrm{\ cGy}}$ . For the two cases, we perform re-planning to reduce the bladder dose to D mean = 3841 cGy ${{\mathrm{D}}}_{{\mathrm{mean}}} = 3841{\mathrm{\ cGy}}$ , D mean = 3580 cGy ${{\mathrm{D}}}_{{\mathrm{mean}}} = 3580{\mathrm{\ cGy\ }}$ under the condition that the PTV meets the prescribed dose. CONCLUSIONWe provide a dose accurate adaptive workflow for prostate cancer patients by